

Paxman publishes newsletter on the internationalisation of the company's patient support website

Today, Paxman publishes the January issue of its newsletter aimed at shareholders, investors and other interested parties.

This month's issue highlights that Paxman has initiated a substantial internationalisation of coldcap.com, the company's patient support website. In January, Arabic, French, German, Italian and Swedish versions went live, and more languages will follow throughout 2022. This much appreciated website is offered to promote Paxman's commitment to making patient education and awareness materials accessible to all, no matter where in the world you are.

The newsletter also includes information on the launch of Paxman's new Changing the Face of Cancer Podcast, where CEO Richard Paxman talks with renowned oncologists, clinical researchers and medical thought leaders on side effect management, orders for several systems to the US, the UK, France, Switzerland, the Netherlands, the Czech Republic, Greece and Brazil, and that the company's partner in Japan is hosting a webinar on January 28 on best practises when implementing scalp cooling.

To read the newsletter and subscribe for upcoming issues, follow this link:

<https://bit.ly/paxjan22en>

Paxman's investor newsletter is published monthly as a part of the company's effort to strengthen its market communication together with the IR communication agency [Honeybadger](#). Every published issue of the newsletter is available on Paxman's website for investors, www.paxman.se. The company encourages feedback and requests on topics for upcoming issues of the newsletter.

Contacts

Richard Paxman, CEO
Tel: +44 7968 020641
Email: richard@paxmanscalpcooling.com
www.paxman.se

About Us

The Paxman Scalp Cooling System has been developed by the Paxman family to reduce hair loss in breast cancer patients undergoing chemotherapy. The concept behind the system came when the mother of four, Sue Paxman, experienced first-hand the trauma of chemotherapy-induced hair loss. With close to 4,000 systems delivered in to hospitals, clinics and treatment centres around the world, PAXMAN is the leading supplier of Scalp Cooling technology. PAXMAN's scalp-cooling cap is made from lightweight, biocompatible silicone that is soft and flexible, providing a snug yet comfortable fit during treatment. PAXMAN AB (publ) has its headquarters in Karlshamn (Sweden), with subsidiaries in Huddersfield (UK) and Houston, Texas (US).

The PAXMAN share is listed on Nasdaq First North Growth Market. FNCA Sweden AB is the company's Certified Adviser and can be contacted via info@fnca.se and +46 (0)8 528 003 99.

Attachments

[Paxman publishes newsletter on the internationalisation of the company's patient support website](#)